Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.

Saskia HussungDilara AkhoundovaJulian HippMarie FolloRhena F U KlarUlrike PhilippFlorian SchererNikolas von BubnoffJustus DuysterMelanie BoerriesUwe WittelRalph M Fritsch

Published in: BMC cancer (2021)

Integrated analysis of cfKRASmut and CA 19-9 levels is a promising approach for molecular monitoring of patients following resection of PDAC. Larger prospective studies are needed to further develop this approach and dissect each marker's specific potential.

Keyphrases

cell free
end stage renal disease
prognostic factors
ejection fraction
newly diagnosed
chronic kidney disease
protein kinase
patient reported outcomes
wild type
circulating tumor
free survival